Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) insider Jonathan Zalevsky sold 5,538 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $60.71, for a total value of $336,211.98. Following the completion of the sale, the insider owned 15,437 shares of the company’s stock, valued at $937,180.27. The trade was a 26.40% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
Jonathan Zalevsky also recently made the following trade(s):
- On Tuesday, May 19th, Jonathan Zalevsky sold 199 shares of Nektar Therapeutics stock. The shares were sold at an average price of $65.51, for a total value of $13,036.49.
Nektar Therapeutics Stock Up 0.1%
Shares of Nektar Therapeutics stock opened at $60.98 on Friday. The company has a market capitalization of $2.06 billion, a price-to-earnings ratio of -7.24 and a beta of 1.13. The stock’s 50-day simple moving average is $73.36 and its 200-day simple moving average is $62.16. Nektar Therapeutics has a 52 week low of $8.27 and a 52 week high of $109.00.
Analyst Upgrades and Downgrades
Several research firms have recently commented on NKTR. Weiss Ratings reissued a “sell (d-)” rating on shares of Nektar Therapeutics in a report on Tuesday, June 2nd. B. Riley Financial reaffirmed a “buy” rating and set a $150.00 target price (up from $105.00) on shares of Nektar Therapeutics in a research note on Monday, February 23rd. TD Cowen initiated coverage on shares of Nektar Therapeutics in a report on Tuesday, March 17th. They issued a “buy” rating on the stock. Jefferies Financial Group reiterated a “buy” rating on shares of Nektar Therapeutics in a research note on Wednesday, April 22nd. Finally, HC Wainwright increased their price objective on shares of Nektar Therapeutics from $165.00 to $185.00 and gave the company a “buy” rating in a report on Monday, April 20th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $149.62.
View Our Latest Stock Analysis on Nektar Therapeutics
Hedge Funds Weigh In On Nektar Therapeutics
Institutional investors have recently bought and sold shares of the business. AQR Capital Management LLC increased its holdings in shares of Nektar Therapeutics by 336.9% in the 1st quarter. AQR Capital Management LLC now owns 3,640,851 shares of the biopharmaceutical company’s stock worth $2,463,000 after buying an additional 2,807,595 shares during the last quarter. Farallon Capital Management LLC purchased a new stake in shares of Nektar Therapeutics during the 3rd quarter valued at about $45,008,000. Two Seas Capital LP bought a new position in shares of Nektar Therapeutics in the 4th quarter valued at about $31,506,000. Prosight Management LP bought a new position in shares of Nektar Therapeutics in the 4th quarter valued at about $23,450,000. Finally, Two Sigma Investments LP grew its position in Nektar Therapeutics by 446.9% in the third quarter. Two Sigma Investments LP now owns 434,237 shares of the biopharmaceutical company’s stock worth $24,708,000 after acquiring an additional 354,842 shares in the last quarter. Institutional investors own 75.88% of the company’s stock.
Nektar Therapeutics Company Profile
Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.
Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.
Featured Stories
- Five stocks we like better than Nektar Therapeutics
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
